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being	 highly	 expressed;	 the	 apparent	
discrepancy	between	our	data	and	those	
reported	by	Hilmi	et al.	may	be	due	to	
one	of	several	factors.	First,	the	authors	
used	 only	 two	 cell	 lines	 in	 their	 stud-
ies,	which	might	have	not	been	enough	
lines	 to	 accurately	 predict	 a	 similar	
association	across	a	larger	sample	size.	
Next,	our	gene	expression	profiling	was	
performed	in	the	continued	presence	of	
excess	 (5	µg/ml)	 insulin,	 rather	 than	 a	
transient	treatment	with	IGF-1	to	serum-
starved	 cells;	 this	 minor	 experimental	
difference	 could	 account	 for	 the	 dis-
crepancy	between	the	two	sets	of	data.
Although	 the	 results	 of	 Hilmi	 et al.	
(2008)	help	to	establish	a	role	for	IGF-1	
signaling	in	expression	of	anti-apoptotic	
molecules,	 they	 leave	 other	 questions	
unanswered.	 For	 example,	 what	 are	
the	 molecular	 mechanisms	 by	 which	
IGF-1	 is	 able	 to	 induce	 expression	 of	
Bcl-2,	 Bcl-XL,	 and	 survivin—are	 these	
proteins	coregulated	or	similarly	affected	
by	distinct	downstream	mediators	of	the	
IGF-1	 signaling	 axis?	 Likewise,	MeWo	
and	 A375	 cells	 represent	 metastatic	
melanomas—is	 the	 prosurvival	 pheno-
type	 after	 IGF-1	 treatment	 a	 function	
of	 disease	 stage	 or	 is	 this	 observation	
merely	coincidental?	Furthermore,	does	
inhibition	of	IGF-1	signaling	(via	IGF-1R	
monoclonal	 antibodies,	 for	 example)	
synergize	with	 traditional	 chemothera-
peutics	 to	 initiate	 disease	 regression?	
These	 types	 of	 studies	 appear	 promis-
ing	in	preclinical	investigations	(Ji	et al.,	
2007;	 Maloney	 et al.,	 2003),	 whereas	
results	 from	 early	 clinical	 trials	 are	
still	pending.
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First-Class Delivery: Getting Growth 
Factors to Their Destination
Jeffrey	M.	Davidson1
Growth factor bioavailability in therapeutic applications such as wound healing 
is limited by extracellular matrix sequestration, proteolysis, and clearance. Local, 
transient delivery by gene transfer is an attractive concept. Many transfection 
strategies are available, and adenoviral vectors are in clinical trials. Keratinocyte 
growth factor-1 (KGF-1), an epithelial-specific member of the fibroblast growth 
factor (FGF) family, has achieved limited success in protein formulations. Matrix- 
and cell-based strategies for delivering a KGF-1 virion to target tissue may 
improve the reproducibility and efficiency of the process, although the advantag-
es of cell-based therapy must be weighed against its added cost and complexity.
Journal of Investigative Dermatology (2008),	128,	1360–1362.	doi:10.1038/jid.2008.128
Despite	 two	 decades	 of	 advancement	
in	the	understanding	and	use	of	growth	
factors	 for	 wound	 healing,	 there	 has	
been	limited	clinical	success	(Leahy	and	
Lawrence,	2007;	Papanas	and	Maltezos,	
2007).	Numerous	strategies	for	transient	
gene	delivery	of	growth	factor	cDNA,	by	
driving	 sustained,	 local	 overexpression	
of	the	factor,	appear	to	overcome	obsta-
cles	to	delivery	of	and	response	to	these	
proteins	 in	 the	 hostile	wound	 environ-
ment	(Eming et al.,	2007).	Transient	gene	
delivery	avoids	many	of	 the	challenges	
of	 stable	 transformation	needed	 to	cor-
rect	 genetic	 defects.	 Among	 the	 many	
potential	 approaches	 for	DNA	 transfer,	
early	 clinical	 findings	 with	 adenoviral	
recombinant	 platelet-derived	 growth	
factor-BB	 (PDGF-BB)	 therapy	 have	
been	 promising.	 Using	 a	 humanized	
mouse	model,	Escámez	et	al.	(2008,	this	
issue)	 have	 compared	 several	methods	
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of	 expressing	 adenovirally	 delivered	
FGF-7/KGF-1	 in	 small	 excisional	
wounds	 with	 a	 principal	 end	 point	 of	
wound	 resurfacing.	 They	 report	 that	
fibrin	 gels	 containing	 either	 free	 virus	
or	 virally	 transformed	 fibroblasts	 yield	
more	consistent	improvement	in	epider-
mal	 closure	 than	 intradermal	 injection	
of	free	adenovirus.
The	authors	previously	described	a	
useful	wound	model	in	which	human	
living	 skin	 equivalents	 (LSEs)	 were	
implanted	 in	 immunodeficient	 mice	
(Escámez	et al.,	2004).	This	approach	
has	 the	 advantage	 of	 standardization,	
analysis	 of	 human	 cells	 in	 a	 tissue	
construct,	and	a	reduced	wound	con-
traction	 artifact,	 with	 the	 limitation	
that	 the	 graft	 develops	 as	 a	 chimera	
of	mouse	vascular	and	hematopoietic	
derivatives	with	 defined	 human	 cuta-
neous	 cell	 populations.	As	 a	 positive	
control	 for	 growth	 factor	 efficacy,	 the	
present	 study	 illustrates	 that	 an	 LSE	
containing	 keratinocytes	 that	 have	
been	 stably	 transformed	 by	 a	 retrovi-
ral	 KGF-1	 vector	 demonstrated	 more	
rapid	closure.	The	potential	drawback	
of	sustained	KGF-1	delivery	is	evident	
from	 the	 hypertrophic	 epidermis	 as	
shown	in	Figure	1	of	the	authors’	arti-
cle	in	this	issue.
KGF-1	 is	 an	 interesting	 choice	 for	
this	study	because	it	is	one	of	the	clear-
est	 examples	 of	 paracrine	 interaction	
between	 the	 expressing	 fibroblast	 and	
the	responding	epidermal	cell	(Werner 
et al.,	 2007).	 Effective	 growth	 factor	
action	requires	short	distances	between	
the	secreting	and	target	cells,	and	mem-
bers	 of	 the	 FGF	 family	 tend	 to	 bind	
quite	strongly	to	heparan	sulfate	proteo-
glycans	in	the	interposing	extracellular	
matrix.	 KGF-1	 presents	 several	 useful	
characteristics	 of	 a	 vulnerary	 agent,	
including	enhanced	epithelial	differen-
tiation	and	protection	against	oxidative	
stress.	The	main	application	for	KGF-1	
has	been	directed	toward	oral	mucosi-
tis	(Radtke	and	Kolesar,	2005;	Siddiqui	
and	 Wellington,	 2005);	 however,	 the	
development	 of	 KGF-2/FGF-10	 for	
chronic	 wounds	 has	 not	 proceeded	
beyond	earlier	trials	on	wound	healing	
(Robson et al.,	2001).	Topical	applica-
tion	of	growth	factors,	at	least	in	simple	
delivery	 vehicles,	 seems	 to	 be	 a	 rela-
tively	ineffective	method	of	drug	deliv-
ery.	 Wound	 healing	 effects	 with	 rhP-
DGF-BB	require	industrial	quantities	of	
protein	with	 potential	 systemic	 effects	
(Steed,	2006),	whereas	gene	delivery	is	
more	efficient	by	several	orders	of	mag-
nitude	(Gu	et al.,	2004).
Escámez	 et al.	 observed	 that	 peri-
wound	 injection	 of	 free	 adenovirus	
expressing	 KGF-1	 was	 effective	 in	
enhancing	wound	resurfacing,	but	 the	
outcome	 was	 extremely	 variable.	 On	
average,	 epidermal	 proliferation	 was	
nonetheless	similar	 to	 the	other	deliv-
ery	 models.	 KGF	 activity,	 in	 terms	 of	
cell	 migration,	 may	 be	 particularly	
sensitive	 to	 the	 distance	 between	 the	
viral	 target	 and	 the	 KGF	 target.	 To	
obtain	 more	 consistent	 effects,	 the	
authors	 then	 compared	 free	 virus	 in	
a	 fibrin	 gel	 overlay	with	 virally	 trans-
formed	fibroblasts	in	a	fibrin	gel.	Both	
of	these	methods	produced	more	con-
sistent	findings,	although	there	was	not	
a	 dramatic	 improvement	 in	 efficacy.	
Others	 have	 advocated	 a	 collagen-
based	 biodegradable	 vehicle,	 which	
is	likely	to	be	more	persistent	(Doukas 
et al.,	2001).	This	study	did	not	address	
the	 potential	 effect	 of	 the	 fibrin	 over-
lay	 alone,	 nor	 did	 it	 include	 a	 direct	
comparison	 with	 rhKGF-1	 protein,	
although	the	authors’	previous	publica-
tion	reported	similar	effects	 for	 inject-
ing	1.5	µg	of	the	protein	on	the	first	3	
days	after	surgery.	According	 to	ELISA	
data	in	the	article	in	this	issue,	adeno-
viral	gene	transfer	produced	biological	
effects	 at	 5-	 to	 10-fold	 lower	 steady-
state	tissue	levels	of	KGF-1,	consistent	
with	 the	enhanced	efficacy	offered	by	
local	transgene	expression.
Do	 these	 findings	 support	 a	 more	
practical	and	 (cost-)	effective	means	of	
realizing	 the	 potential	 of	 growth	 fac-
tors?	The	authors	suggest	that	both	gel-	
mediated	methods	are	superior—at	least	
in	 terms	 of	 reproducibility—to	 simple,	
peri-wound	injection.	They	further	sug-
gest	 that	 the	 cell-based	 approach	 can	
have	 higher	 efficiency	 because	 of	 the	
higher	KGF-1	levels	achieved,	although	
the	outcomes	of	each	treatment	in	terms	
of	closure	and	proliferation	were	indis-
tinguishable.	Current	clinical	trials	with	
adenoviral	 PDGF-BB	 utilize	 free	 ade-
novirus	in	a	collagen	gel	matrix	that	 is	
applied	to	the	wound	surface	(Gu et al.,	
2004)	or	 injected	into	the	wound	mar-
gin	 (Margolis et al.,	 2000,	 2004).	The	
practical	 advantages	 of	 a	matrix-based	
delivery	system	are	convenience,	persis-
tence,	and	adhesion	to	the	wound	site.	
Injection,	on	the	other	hand,	can	target	
deeper	tissues;	however,	because	KGFs	
exclusively	bind	to	epithelial	receptors,	
the	expressed	gene	product	may	fail	to	
diffuse	 to	 its	 target.	Deeper	 infiltration	
may	not	be	a	disadvantage	for	treatment	
of	 the	dermis	with	other	growth	 factor	
vectors.	The	cell-based	 system	 is	more	
sophisticated	 and	 has	 the	 potential	
advantage	of	standardizing	the	amount	
of	 growth	 factor	 produced	 because	
the	 cells	would	 be	 infected	with	 virus	
in vitro.	 Cell-based	 therapies	 for	 burn	
and	wound	treatments	are	widely	prac-
ticed,	 and	 at	 least	 three	 separate	 LSE	
technologies	 have	 been	 commercially	
developed.	Thus,	 this	 report	 is	a	useful	
proof	of	principle	 that	exogenous	cells	
can	be	applied	to	wounds	and	used	to	
stimulate	 repair	 through	 either	 endog-
enous	or	transduced	expression	of	heal-
ing	agents.
Escámez	et al.	(2008)	created	the	cel-
lular	system	by	infecting,	washing,	and	
incubating	cells	and	transplanting	them	
to	the	wound	site.	This	would	be	a	com-
plex	and	costly	approach	and	not	easily	
scaled	 or	 transported	 to	 the	 clinic.	 If	
autologous	fibroblasts	were	used	in	this	
application,	additional	delay	would	be	
imposed	by	the	expansion	of	donor	cell	
populations.	The	transient	expression	of	
adenoviral	genes	may	make	 it	difficult	
to	execute	this	therapy,	except	at	facili-
ties	 that	 are	 equipped	 to	manage	 cell	
culture	 for	 human	 therapy.	The	 use	 of	
allogeneic	cells	with	stable	or	regulated	
transgene	expression	would	be	a	more	
promising	tactic.
Cell-based	 wound	 healing	 strate-
gies	 have	 used	 autologous	 or	 allo-
geneic	 sources	 of	 keratinocytes,	
fibroblasts,	 mesenchymal	 stem	 cells,	
and	 unfractionated	 marrow.	 Tissue	
equivalents,	 containment	devices,	 and	
|Cell-based	wound	healing	strategies;	candidates	for	genetic	
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cell	suspensions	in	biological	matrices	
have	been	used	to	immobilize	the	cells	
and	to	permit	interactions	with	the	host	
tissue	(Lanza et al.,	2007).	There	is	very	
little	 evidence	 that	 these	 devices—at	
least	 in	 the	wound	environment—lead	
to	integration	or	long-term	survival,	yet	
there	 is	 not	 compelling	 evidence	 for	
rejection.	The	presumed	mode	of	action	
for	an	LSE	is	paracrine	stimulation,	per-
haps	in	response	to	the	wound	environ-
ment.	It	has	been	obvious	for	some	time	
that	 these	 cell-based	 cutaneous	 treat-
ments	 are	prime	candidates	 for	 genet-
ic	 manipulation	 if	 safety	 and	 efficacy	
issues	 can	 be	 satisfactorily	 resolved.	
However,	it	is	not	certain	that	the	added	
costs	of	production	and	safety	measures	
can	yield	a	cost-effective	drug	delivery	
system.	Cell	systems	that	are	engineered	
to	deliberately	express	one	or	more	bio-
logicals	would	fall	under	more	stringent	
regulatory	 scrutiny.	 One	 can	 envisage	
a	 strategy	 in	which	 cell-based	healing	
devices	are	customized	to	deliver	vari-
ous	doses	of	various	 factors,	 including	
proteinase	inhibitors,	depending	on	the	
type	of	wound	and	the	stage	of	healing.	
The	effects	 seen	 in	 this	model	 system,	
which	uses	a	human	skin	equivalent	as	
opposed	 to	 intact	 human	 tissue,	 point	
in	a	positive	direction.
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Filaggrin Mutations and Allergic 
Contact Sensitization
Jon	M.	Hanifin1
In this issue, novak et al. (2008) provide evidence that filaggrin barrier defects 
might also predispose to allergic contact dermatitis by allowing greater penetra-
tion of chemical haptens. Their report provides a fresh perspective on the issues 
of contact allergy, nickel sensitization, and stratum corneum defects.
Journal of Investigative Dermatology (2008),	128,	1362–1364.	doi:10.1038/sj.jid.5701253
The	 eczemas	 comprise	 a	 family	 of	
inflammatory	skin	diseases	that	have	as	
hallmarks	 itch,	 epidermal	 spongiosis,	
and	disruption	of	the	stratum	corneum	
barrier.	 Atopic	 dermatitis	 (AD)	 and	
allergic	 contact	 dermatitis	 (ACD)	 are	
among	 the	most	 common	 and	widely	
studied	of	the	eczemas.	In	the	spring	of	
2006	a	revealing	new	light	focused	on	
AD,	firmly	associating	that	disease	with	
ichthyosis	vulgaris	and	loss-of-function	
mutations	 in	 the	 filaggrin	 (FLG)	 gene	
(Palmer	 et al.,	 2006),	 and	 subsequent	
studies	 have	 confirmed	 that	 finding	
(Irvine,	2007).	This	insight	gave	molecu-
lar	support	to	long-standing	predictions	
that	AD	might	be	caused	by	an	epider-
mal	barrier	defect	allowing	penetration	
of	irritants,	microbes,	and	protein	anti-
gens	(Wood	et al.,	1992).
Those	 revelations	 led	 naturally	 to	
the	 question	 of	 whether	 FLG	 barrier	
defects	might	 also	 predispose	 to	ACD	
by	 allowing	 greater	 penetration	 of	
chemical	haptens.	In	this	issue,	Novak	
and	 collaborators	 in	 Germany	 pro-
vide	evidence	 that	 the	answer	may	be	
yes	 (Novak	 et al.,	 2008).	These	 inves-
tigators	 looked	 for	 two	 common	 FLG	
mutations	 in	 a	 cross-sectional	popula-
tion	 that	 had	 been	 studied	 and	 patch	
tested	with	 common	 chemicals	 in	 the	
KORA	Allergy	Study	from	1994	to	1995	
(Schäfer	 et al.,	 2001).	 They	 selected	
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